TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06462235: A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BI

Sponsor: Pfizer · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 48 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$352,800

Rescue Site Savings

+$235,200

Unlock Full NCT06462235 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06462235 Rescue Dossier →